NCT07225556Active, not recruitingPhase 1
A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy
A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Source: ClinicalTrials.gov · Last updated 29 Jul 2026
Brief summary (registry, in English)
The purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last approximately 7 months.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- First submitted
- 20 Oct 2025
- Start date
- 18 Nov 2025
- Primary completion date
- Dec 2026
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Obesity
- NCT number
- NCT07225556
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 84
- From 18 Nov 2025 to the primary completion date, Dec 2026
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study drug, or of interfering with the interpretation of data.
Other
- Is an individual of childbearing potential (IOCBP)
Who the study is looking for
- Participant must be 21 for Singapore site
- Have a body mass index (BMI) between 27.0 kilogram per square meter (kg/m²) and 35.0 kg/m², inclusive
- Have had a self-reported stable weight for 3 months prior to screening (less than approximately 5 percent \[%\] body weight change)
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lilly Centre for Clinical Pharmacology Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
| Fortrea Clinical Research Unit Coordinator of this site? Confirm its status | Madison | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.